The novel peptide synthesis protocol allows the synthesis of multiple peptide fragments on a single bead.

JAG201 gene replacement therapy available to both child and adult patients is now in Phase I clinical trial.

Can CAR T, which has had successes in immuno-oncology, be applied to reset the immune system of autoimmune disease patients?

The fast track designation means that the clinical development and regulatory milestones of the drug candidate are likely to progress much faster.

In 2020 Jennifer Doudna & Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for discovering the revolutionary gene-editing tool CRISPR/Cas9. This article shines a spotlight on their remarkable achievements and addresses current applications and future opportunities for CRISPR/Cas9.

The breakthrough in mouse models will allow researchers to study the human immune system in far greater detail at a far greater pace.

CureVac will continue to build its R&D pipeline while allowing GSK to develop and commercialise a handful of its prophylactic mRNA vaccines.